DNA vaccination was employed to study immune responses to hepatitis C virus (HCV) proteins. As an immunizing strategy, we studied immune responses of BALB/c (H-2d) and C57BL/6 mice (H-2b) to HCV genes delivered intramuscularly as a polycistronic construct capsid/E1/E2/NS2/NS3 (pRC/C-NS3) encoding 5 structural and nonstructural proteins. We also evaluated canarypox virus containing the same HCV genes as a means for potentiating immune responses to naked DNA. Our results indicate that mice that received a polycistronic pRC/C-NS3 with canarypox booster had enhanced antibody and cellular responses to HCV proteins. Immunodominant CD8 + T cell responses to several HCV structural and nonstructural proteins, characterized by cytotoxicity and interferon (IFN)-g production or IFN-g production without significant cytotoxicity, were observed in both strains of mice. The combination of naked DNA with a nonreplicating canarypox booster encoding HCV polycistronic pRC/C-NS3 genes appears to diversify and enhance T cell responses to HCV proteins.
DNA vaccination was employed to study immune responses to hepatitis C virus (HCV) proteins. As an immunizing strategy, we studied immune responses of BALB/c (H-2d) and C57BL/6 mice (H-2b) to HCV genes delivered intramuscularly as a polycistronic construct capsid/E1/E2/NS2/NS3 (pRC/C-NS3) encoding 5 structural and nonstructural proteins. We also evaluated canarypox virus containing the same HCV genes as a means for potentiating immune responses to naked DNA. Our results indicate that mice that received a polycistronic pRC/C-NS3 with canarypox booster had enhanced antibody and cellular responses to HCV proteins. Immunodominant CD8 + T cell responses to several HCV structural and nonstructural proteins, characterized by cytotoxicity and interferon (IFN)-g production or IFN-g production without significant cytotoxicity, were observed in both strains of mice. The combination of naked DNA with a nonreplicating canarypox booster encoding HCV polycistronic pRC/C-NS3 genes appears to diversify and enhance T cell responses to HCV proteins.
Hepatitis C virus (HCV) has a worldwide seroprevalence of 1%-3% and is responsible for most cases of non-A, non-B hepatitis. At least 50% of transfusion recipients with acute HCV infection develop chronic or recurrent liver disease that may progress to cirrhosis or hepatocellular carcinoma [1] . Unlike hepatitis B virus, in which plasma-derived or recombinant protein vaccines encoding the surface antigen evoke strong immune responses and protection, properties such as the high variability of genotypes and quasi species [2] make it unlikely that a recombinant protein-derived vaccine would be effective for protection against diverse strains of HCV. Cell-mediated immune responses such as CD8 ϩ cytotoxic T lymphocytes (CTL) may play an important role [3] [4] [5] and are better correlated with protection against HCV [6] .
To develop a vaccine against HCV, it is important to define a strategy that evokes strong immune responses to variable and conserved regions of the virus. Many CTL epitopes have been defined for all HCV gene products [7] . A polycistronic immunogen that includes CTL of many specificities, some of which HCV genes that induced immune responses to HCV NS3, NS4, and NS5 proteins [22] . In other studies, immunization with peptides from HCV core and nonstructural RNA polymerase NS5 regions has revealed additional immunogeneic peptides that, in some cases, appear to be cross-reactive and recognized by CTL in mice and humans [23, 24] .
In this study, we compared the immunogenicity of a large polycistronic plasmid vector encoding HCV capsid/E1/E2/NS2/ NS3 (pRC/C-NS3) delivered either as plasmid DNA, as recombinant canarypox (ALVAC) expressing the same HCV genes, or in combination, using an HCV DNA-prime and a canarypox boost. Cellular immune responses were studied by CTL induction and by interferon (IFN)-g production by enzyme-linked immunospot (ELISPOT) assay. The frequency and specificity of CD8 ϩ T cell responses for individual HCV gene products was quantified by using recombinant vaccinia viruses expressing individual HCV genes to detect antigen-specific responses in BALB/c (H-2d) and C57BL/6 (H-2b) strains of mice. We show that (1) immunization with plasmid DNA encoding the polyprotein C-NS3 induces cellular immune responses to HCV structural and nonstructural proteins; (2) incorporation of a canarypox (ALVAC) booster in the immunization regimen further potentiates cellular immune responses observed with DNA immunization; and (3) immunodominance of cellular immune responses to HCV proteins after DNA/pox immunization is determined by mouse haplotype and can be characterized either by IFN-g production or by stimulating both CTL and IFN-g production. These results have implications for vaccine design and control of virus replication.
Materials and Methods
Animals. Female BALB/c mice, obtained at 6-8 weeks of age from the Jackson Laboratory (Bar Harbor, ME), and C57BL/6 mice (bred in-house) were housed in the New York Blood Center pathogen-free animal research facility.
Plasmid constructs for immunization. HCV cDNA sequences were derived from pRC/B2, a plasmid containing the entire openreading frame of the HCV-BK strain [25] inserted into the vector pRC/CMV (Invitrogen). Partial HCV genes were cloned into expression vector pRC/ATG, which was generated by inserting a double-stranded oligonucleotide containing the Kozak ATG consensus sequence produced by annealing the oligonucleotide 5 -AGCTTGCCACCATGGC-3 and 5 -GGCCGCCATGGTGGCA-3 into the HindIII and NotI sites of the polylinker of pRC/CMV. To express HCV genes, each coding sequence was amplified by polymerase chain reaction and cloned into pRC/ATG with NotI and XbaI restriction sites. The constructs did not contain the HCV 5 untranslated region. Recombinant plasmid DNA was prepared with Qiagen Giga prep columns (Qiagen, Chatsworth, CA) and Qiagen endotoxin removal buffers. Plasmid DNA was resuspended in sterile PBS after ethanol precipitation. Levels of endotoxin were determined using the Limulus Amoebocyte Lysate QCL-1000 kit (Biowhittaker, Walkersville, MD) and were !20 endotoxin units/ mg DNA.
In vitro expression of plasmid constructs. To ensure that plasmid DNA constructs were intact and functional, the plasmids were sequenced across the gene inserts, and expression was analyzed in vitro by transient transfections. In vitro expression of pRC/CMV-HCV plasmids was detected in tissue culture by transient transfections in COS-1 cells (American Type Culture Collection, Rockville, MD) with corresponding constructs. COS-1 cells at 5 2 ϫ 10 cells/well in 6-well plates were transfected with plasmid pRC/C-NS3 with lipofectin reagent (GIBCO BRL, Gaithersburg, MD) according to the manufacturer's instructions. Control cells were transfected with pRC/ATG vector only. After a 5-h incubation with serum-free OPTI-MEM (GIBCO BRL) at 37ЊC, 5% CO 2 , an equal volume of OPTI-MEM containing 20% fetal calf serum (FCS) was added. Cells were reincubated at 37ЊC for another 48 h and then washed with PBS and lysed with 100 mL of SDS gel-loading buffer/ well containing 100 mM Tris at pH 6.8, 100 mM dithiothreitol, 2% SDS, 10% glycerol, and bromophenol blue. The lysates were scraped into microcentrifuge tubes, boiled for 10 min, sheared by sonication, and centrifuged. The supernatant proteins were separated in 10%-12% SDS-polyacrylamide gel and transferred to PGC nitrocellulose membranes for Western blotting. The nitrocellulose membranes were soaked overnight at 4ЊC in a blocking buffer containing 5% nonfat milk and PBS. Ratios of 1:500-diluted rabbit anti-HCV NS3 or 1:500-diluted serum from an N3/93-infected blood donor, selected for a high titer of broadly reactive antibodies to HCV proteins, or monoclonal antibodies (MAbs) to individual E1 and E2 proteins were applied to the membrane and incubated at room temperature for 1 h, followed by incubation in 1:3000-diluted peroxidase-conjugated goat anti-rabbit IgG or goat anti-human or anti-mouse IgG (Amersham, Cleveland) for 1 h at room temperature. The blots were developed with ECL reagent (Amersham).
Poxvirus constructs. HCV genes from HCV-BK (genotype 1b) were inserted into 2 poxvirus vectors: ALVAC, a vaccine strain of canarypox [26] , and the L-variant of WR, a laboratory strain of vaccinia virus [27, 28] . The ALVAC-based recombinants include HCV sequences encompassing capsid through NS3 (capsid/E1/E2/ NS2/NS3), which were placed under the control of the synthetic vaccinia early/late H6 promoter [29] . This expression cassette was inserted into a canarypox donor plasmid flanked by genomic sequences from which a nonessential gene was specifically deleted. Recombination between the donor plasmid and the ALVAC virus resulted in the recombinant ALVAC-capsid/E1/E2/NS2/NS3. This recombinant virus was used to stimulate mouse splenocyte effector cells and also as a booster for DNA-based immunization.
The vaccinia (WR)-based recombinants were constructed for use in CTL assays and were generated for each of the HCV genes capsid, E1, E2, NS2, and NS3. The capsid gene was expressed under the control of the vaccinia H6 promoter. The remaining genes were expressed under the control of an early entomopox promoter. Expression cassettes were inserted immediately downstream from the KIL host range gene [30] in the WR strain of vaccinia virus. The inserts were resequenced and were found to correspond to the sequence of the parental clones.
HCV protein expression by these recombinant pox viruses was determined by SDS-PAGE and by Western blots 2 days after infection of COS-1 cells.
Plasmid DNA immunization. Groups of 20-24 BALB/c and C57BL/6 mice were injected intramuscularly with 100 mg of each pRC/C-NS3 in a 50-mL volume in both quadriceps. Mice were boosted with the same amount of DNA at 4 and 8 weeks after priming. At week 12, half of the animals in each group were boosted intravenously (iv) with pfu of ALVAC (canarypox vector) 7 5 ϫ 10 containing the C-NS3 genes. Control mice were injected with pRC/ C (not containing a gene insert) in saline and likewise received iv pfu of ALVAC parent construct lacking the HCV genes. Mouse serum from unimmunized animals and animals injected with the empty-plasmid vector pRC/C served as controls. Seroconversion and antibody titers were evaluated using serial dilutions of serum samples. The cutoff for seroconversion was defined as the mean optical density SD for 5 serum samples obtained (OD) ‫ע‬ 3 from mice immunized with control plasmid DNA (pRC/C) lacking the HCV gene.
Preparation of effector cells. Single-cell spleen cells were isolated mechanically between the ground glass surface of 2 slides and by lysing red blood cells with 1.66% ammonium chloride. All cells were cultured at 37ЊC in 5% CO 2 for 5 days in complete tissue culture medium (TCM: RPMI 1640 supplemented with 10% (v/v) FCS, 1.5 mM L-glutamine, 50 mM 2-ME, 100 U/mL penicillin, and 100 U/mL streptomycin). Spleen cells from DNA-vaccinated BALB/c mice ( /mL) were restimulated in vitro with irra- 6 5 ϫ 10 diated (3000 rads) syngeneic spleen cell stimulators (10 6 /mL) after pulsing these for 1 h at 37ЊC with ALVAC (C-NS3) construct at an MOI of 10. Cultures were set up in 24-well plates, and interleukin-2 was not added in this assay. 5 ϫ 10 to each well of a U-bottom 96-well plate. Effector cells (100 mL) were added to the target cells in triplicate wells at various effectorto-target (E:T) ratios. For each target, 6 replicate wells with medium alone and 6 with 5% Triton-X were included for spontaneous release and total release, respectively. The plates were spun for 5 min at 149 g in a bench-top centrifuge and were incubated at 37ЊC for 6 h. Supernatants (100 mL) from each well were counted in a 1250 Microbeta gamma counter (Wallac, Gaithersburg, MD Cr release release Ϫ spontaneous release)] ϫ 100 assays were performed in parallel with the ELISPOT assays to serve as a control for virus-specific killing.
Preparation of stimulator/target cells. Exponentially growing P815 (H-

Determination of IFN-g-secreting cells and cell phenotype by ELISPOT and FACS analysis.
The ELISPOT assay was set up as described earlier [31] , with a few modifications. In brief, in vitro-stimulated spleen cells ( ) were cultured in 100 mL 3 5 10 Ϫ 5 ϫ 10 of TCM in triplicate wells in nitrocellulose-bottomed Millititer HA plates (Millipore, Bedford, MA) precoated with 75 mL of a 10 mg/ mL monoclonal rat anti-mouse IFN-g antibody (clone XMG1.2, Pharmingen). Vaccinia virus-infected P815 stimulator cells (10 5 ) were added after irradiation (10,000 rads). Plates were incubated overnight at 37ЊC and then washed and incubated with 100 mL of a 5 mg/mL solution of biotin-labeled rat anti-mouse IFN-g antibody for 2 h. The plates were washed and incubated at room temperature with streptavidin-alkaline phosphatase (1:800) for 15 min. After additional washings, 100 mL of enzyme-substrate solution (3,3 -diaminobenzidine-tetra-hydrochloride dihydrate) was added, and spots were allowed to develop for 10-15 min. The color reaction was stopped by washing the plates with distilled water. After drying, the spots were counted under low magnification (ϫ40) by using a stereo microscope. Antigen-induced responses were considered positive if the number of spots was greater than the SD of those in wells stimulated with vaccinia parent for mean ‫ע‬ 3 each individual animal group. Statistical significance was determined using Student's t test.
For determining cell phenotype of IFN-g-producing cells, in vitro-stimulated effector spleen cells were incubated for 16 h with irradiated (10,000 rads) P815 tumor cells after infection with vaccinia virus constructs encoding HCV proteins. Golgi Plug (Pharmingen, San Diego, CA) was added during the last 6 h of incubation, to concentrate the levels of intracellular cytokines. The cells were then washed and stained for cell surface CD4-or CD8-fluorescein isothiocyanate (FITC; 1 mg/million cells; Pharmingen), fixed, permeabilized, and stained for intracellular IFNg-PE (0.25 mg; PE-XMG1.2), by use of the Cytofix/Cytoperm Plus kit (Pharmingen) according to the manufacturer's instructions. Cells were analyzed in a FACScan flow cytometer (Becton Dickinson, Mountain View, CA). The quadrant markers for the bivariant dot blots were set on the basis of the negative staining controls, using isotype-matched immunoglobulin controls (FITC-rat IgG2a and PE-rat IgG1, Pharmingen).
Results
Expression of HCV structural proteins after cell transfection.
Cell lines were transfected with plasmid pRC/C-NS3 encoding HCV capsid, E1, E2, NS2, and NS3. Antigen expression in transiently transfected cells was determined by immunoblots of cell lysates from transfected COS-1 cells that were probed with sera or MAbs reactive to HCV proteins. Figure  1A shows the detection of the 18-21-kDa capsid protein in cells transfected with plasmids encoding C-NS3. The expression of NS3 in plasmid pRC/C-NS3 was detected as a band of 70-kDa protein ( figure 1A ). These bands were present only in the recombinant plasmid lanes and not in the control plasmid lanes (pRC/ATG). Although expression of E1 and E2 proteins was not detectable by Western blot in pRC/C-NS3-transfected responses were determined 4 and 8 weeks after the canarypox boost.
In vivo HCV-specific humoral antibody responses. As shown in figure 2, specific antibodies to HCV recombinant antigens were detected in the serum of DNA-immunized mice. In both BALB/c and C57BL/6 mice immunized with pRC/C-NS3 plasmid DNA, however, antibody responses to HCV proteins were detected only after canarypox (ALVAC C-NS3) boosting. No HCV-specific antibodies were detected in mice vaccinated with control empty-plasmid DNA vector (figure 2) or in mice immunized with ALVAC (C-NS3) alone in the absence of DNA immunization (data not shown). The greatest OD values were obtained in most responding mice 4 weeks after receiving AL-VAC (C-NS3) boost. Both the level of antibody responses and seroconversion rates (80% for BALB/C and 60% for C57BL/6 mice) were increased with canarypox boosting. The antibody responses shown are the total IgG responses to recombinant HCV proteins.
HCV-specific cell-mediated immune responses. CD8 ϩ T cell responses induced by DNA/canarypox immunization regimens were monitored using IFN-g ELISPOT and 51
Cr-release assays. The protective relevance of the highly sensitive ELISPOT assay is supported by the observation that, during certain viral infections, IFN-g can inhibit viral replication in vivo in the absence of CTL [3] . In both assays, we used vaccinia virusencoded individual HCV genes to infect target cells to study CD8 ϩ T cell responses to endogenously processed HCV proteins. Vaccinia vectors are considered more useful than peptides, because the vector permits production of the whole protein ( figure 1B ) and therefore can elicit responses to many peptides and to all possible haplotypes.
IFN-g secretion and effector cell phenotype. In both the BALB/c and C57BL/6 strains of mice (table 1), immunization with plasmid DNA construct-encoding HCV pRC/C-NS3 genes induced significant IFN-g production in response to stimulator cells infected with vaccinia-encoded HCV C-NS3 proteins, as compared with control mice that received empty-plasmid DNA vector (pRC/C). The IFN-g response was further potentiated in both strains after recombinant canarypox AL-VAC (C-NS3) boosting. On dissection to examine responses to individual HCV proteins, maximal IFN-g secretion was observed to envelope glycoprotein E1 in BALB/c mice ( cells) by effector T cells (table 1) . IFN-g 6 90,680 ‫ע‬ 3302/10 secretion was also observed in response to P815 cells expressing HCV capsid ( cells), E2 ( cells), 6 6 1120 ‫ע‬ 38/10 1680 ‫ע‬ 27/10 NS2 ( cells), and NS3 ( cells) proteins 6 6 505 ‫ע‬ 7/10 1117 ‫ע‬ 33/10 (table 1). The IFN-g ELISPOT responses in C57BL/6 mice after immunization with pRC/C-NS3 were obtained to HCV proteins capsid, E1, E2, NS2, and NS3 (table 1) . Maximal IFN-g secretion was observed in response to HCV NS2 (81,820 ‫ע‬ cells) and to NS3 ( cells) after AL- 6 6 3530/10 88,320 ‫ע‬ 9900/10 VAC HCV C-NS3 boosting. Recombinant canarypox boosting also enhanced the number of spot-forming cells 13 Golgi plug was added during the last 6 h of culture to concentrate intracellular cytokine levels. The splenocytes were harvested, stained with fluorescein isothiocyanate-conjugated rat anti-mouse CD8, fixed, permeabilized, and subsequently stained with phycoerythrin-conjugated rat anti-mouse IFN-g antibody. The percentages of both the CD8-and IFN-g-positive cells are depicted in the upper-right quadrants. figure 3B ) and, predominantly, in response to E1 envelope glycoprotein of HCV ( figure 3D ) in BALB/c mice. No CD4, IFN-g-secreting cells were observed (data not shown). The intracellular staining for IFN-g was highly specific and could be blocked by competition with large amounts of recombinant IFN-g (data not shown).
As a control for the DNA prime-pox boost approach, we also compared the efficacy of both priming and boosting with recombinant canarypox vector encoding HCV C-NS3 proteins for the generation of CTL and IFN-g immune responses in BALB/c mice. Compared with DNA and DNA-pox immunization with C-NS3 genes, weak IFN-g ELISPOT responses to all HCV proteins were observed ( (table 1) .
Overall, the ELISPOT was found to be a sensitive assay for characterizing CD8
ϩ T cell activation to naturally processed viral epitopes and consequent IFN-g production, because fewer cells were required and more quantitative results could be obtained. The possibility of concomitant activation of both CD4 and CD8 T cells for the production of IFN-g was prevented by using P815 mastocytoma (H-2d) and EL-4 (H-2b) cells, which express only class I but not class II MHC molecules.
CTL responses. The CTL assays were set up in parallel with the ELISPOT assays, using vaccinia-encoded HCV proteins. Several E:T ratios were studied. In BALB/c mice that received HCV plasmid DNA pRC/C-NS3 without canarypox boosting (HCV DNA prime and boost; figure 4A) , the CTL activity was demonstrated only against the envelope E1 glycoprotein region (24% specific lysis at an E:T ratio of 50:1). Mice that received the HCV pRC/C-NS3 construct and canarypox boost (DNA prime-canarypox boost; figure 4B) had higher and broader CTL specificities to HCV proteins (E1, 44%; E2, 22%; and NS2, 15% specific lysis at E:T ratio 50:1). Lysis of target cells expressing wild-type vaccinia (WR-P) was !5% (figure 4). Unlike IFN-g responses, the CTL responses to HCV capsid ( ) and NS3 ( ) were not substan-8% ‫ע‬ 1% 11% ‫ע‬ 3.6% tially enhanced after canarypox boosting.
As compared with BALB/c mice, the C57BL/6 (H-2d) mice showed stronger CTL responses to HCV structural and nonstructural proteins after immunization. CTL responses of 16.4% (E1), 32.6% (NS2), and 56.6% (NS3) were obtained in mice immunized with HCV plasmid DNA (HCV DNA prime and boost; figure 5A ) at an E:T ratio of 50:1. Boosting with HCV recombinant canarypox (HCV DNA prime-canarypox boost; figure 5B ) enhanced CTL responses to several HCV proteins (E2, 34.6%; NS2, 53.1%; and NS3, 62.4%). CTL responses to HCV capsid (6.9%) and E1 envelope glycoprotein (16.4%) were not enhanced after canarypox boosting ( figure 5 ). The observed CTL activity was determined to be mediated by CD8 ϩ T cells, as indicated by inhibition of lysis after treatment of effector spleen cells with Lyt 2.2 (anti-CD8) antibodies. Treatment with anti-CD4 antibody (clone GK 1.5) did not result in a significant reduction in specific lysis (data not shown). The specificity of the CTL responses to HCV proteins was evidenced by lysis of target cells expressing HCV C-NS3 and lack of CTL responses to wild-type vaccinia (WR-P) and target cells expressing recombinant vaccinia virus encoding the b-Gal protein (figure 6). Lysis of Yac-1 cells was obtained in groups of mice that received HCV plasmid DNA and was enhanced in mice receiving canarypox boosters, providing evidence for NK cell activation in the immunized animals ( figure 6 ). The increase in NK cell activity could be due to canarypox or the possibility that the 2 DNA plasmids, including pRC/control, contain immunostimulatory sequences.
Immunization of mice with recombinant canarypox expressing HCV C-NS3 proteins (in the absence of plasmid DNA) did nor reveal any significant lysis (!10% specific lysis) to any of the HCV proteins, even after у1 boosts (data not shown). Similar results were obtained in mice immunized intraperitoneally with the recombinant canarypox constructs (data not shown).
Discussion
HCV is a highly heterogeneous virus, with CTL epitopes present within both conserved and variable regions of the genome [7, 32] . It is well recognized that CD8 ϩ T lymphocytes mediate important effector mechanisms of immunity against intracellular pathogens such as viruses. These T cells recognize small peptides, which are presented on the surface of infected cells by class I MHC molecules [33] . DNA-based immunization, compared with immunization with soluble recombinant proteins, has the ability to induce strong T-helper cell responses as well as CD8 ϩ CTL activity, presumably because of intracellular processing of viral peptides within muscle and antigenpresenting cells. In contrast to synthetic peptide immunization, in which only a limited number of epitopes can be used, all naturally occurring T-helper and CTL epitopes of each encoded protein are available for recognition by T cells [10] .
One issue in vaccine development, particularly for HCV vaccines, is whether several antigens can be combined in the same vaccine, thus achieving better protection. The potential to design a vaccine encompassing several epitopes may be a major advantage of genetic immunization. As an immunizing strategy, we studied humoral and cellular responses to HCV genes delivered in a polycistronic construct encoding 5 structural and nonstructural HCV antigens: capsid/E1/E2/NS2/NS3. As a part of this strategy, we also evaluated canarypox virus containing the HCV genes as a means for further potentiating immune responses to naked DNA. The generation of protective cellmediated responses by DNA prime and poxvirus booster immunizations has precedence in studies of mice that used the modified vaccinia virus Ankara [34] and studies of macaques that used recombinant fowlpox virus [35] . Inoculation of these highly attenuated [36] and efficacious poxvirus-based vectors has shown successful immunization against many viruses, including human immunodeficiency virus type 1, by inducing strong antibody and memory CD8 ϩ CTL responses [8, 37] or by other as yet undefined mechanisms.
Our results indicate that, although HCV-specific cellular immune responses are induced by naked polycistronic HCV capsid/E1/E2/NS2/NS3 plasmid DNA, the inclusion of canarypox booster potentiates both the antibody-and cell-mediated immune responses to HCV antigens in both the BALB/c and C57BL/6 strains of mice (table 1; figures 4-6). Immune responses to several HCV structural and nonstructural proteins were induced in mice immunized with this approach, as compared with mice that received only plasmid DNA or only recombinant canarypox vectors expressing the same HCV genes. The immunodominance pattern of HCV protein recognition (suggested by strong CTL and IFN-g production) differed in the 2 strains of mice. The envelope E1 glycoprotein dominated immune responses in BALB/c (H-2d) mice, and the nonstructural NS2 and NS3 proteins were predominantly recognized in C57BL/6 (H-2b) mice. The distinct mouse haplotypes, preferential use of different accessory cells for antigen presentation, and the regulatory activities of cytokines themselves may influence the observed immune responses.
Genetic immunization has been attempted with HCV genes in mice. Investigators have studied cellular and/or humoral immune responses to HCV nucleocapsid, envelope E2, or nonstructural NS3, NS4, and NS5 genes delivered alone [16, 17, 19, 22] or delivered with nucleocapsid as chimeric vectors after fusion with hepatitis B virus (HBV) surface antigens [18] . Attempts to combine HCV capsid and envelope proteins in the same construct [20] were shown to decrease both the rate and titer of antibody seroconversion. In these studies, only mice injected with plasmid DNA that included capsid showed CTL responses. Absence of cellular responses to envelope in that study [20] may be due to lack of a sensitive assay for measuring weak CTL activities, such as the ELISPOT assay.
In the present study, we performed CTL assays in parallel with the IFN-g ELISPOT assays to serve as a control for virusspecific killing. It is interesting that T cell recognition of the naturally processed form of capsid in C57BL/6 mice, and of capsid and NS3 in BALB/c mice, was associated with IFN-g release but with no direct or weak cytotolytic activity, even after canarypox boosting (figures 4 and 5). Whether this denotes 2 functionally distinct T cell populations mediating different functions (IFN-g production vs. CTL) is presently not known.
Epitopes of this phenotype, however, might be of interest, especially for immune therapy for chronic HCV infection by associating the benefit of localized lymphokine release with low or absent direct cytopathicity to infected hepatocytes. Several lines of evidence have suggested the important role of IFN-g in the control of viral replication [38] . Passive transfer of class I restricted CTLs led to clearance of the expression of HBV antigens in HBV transgenic mice. The mechanism involved appeared to be nonlytic and mediated by IFN-g and TNF-a [3] .
The observation that DNA priming and canarypox boosting with multiple HCV capsid/E1/E2/NS2/NS3 genes enhance immune responses to structural (capsid and envelope) and nonstructural HCV proteins has important implications. It has been reported that, during natural HCV infection, structural proteins such as capsid and NS3 stimulate strong T cell responses that appear enhanced during viral clearance [39] [40] [41] . The protective efficacy of HCV envelope E1 and E2 glycoproteins has been evaluated by Choo et al. [42] , who showed that chimpanzees immunized with these recombinant proteins were protected against a homologous HCV virus challenge. Humoral responses were observed to E2, but cross-protection against heterologous strains of HCV was not tested in this study. HCV envelope E1 glycoprotein recently was shown to be useful as a therapeutic vaccine for chronic HCV disease in chimpanzees [43] . Although it is likely that candidate vaccines against HCV will include the envelope gene product, it is clearly desirable that these vaccines elicit broad cross-reactive immunity capable of conferring protection against different strains and quasi species of HCV. It is encouraging, therefore, that the DNA prime-pox boost immunization approach with an HCV polycistronic construct encoding multiple HCV genes can stimulate immune responses to several HCV proteins, including the envelope glycoproteins.
The potency or magnitude of immune responses generated by HCV DNA prime-pox boost immunization is greater than that of HCV DNA prime-boost and greater than that of canarypox prime-boost. Immunization with recombinant canarypox encoding the same HCV genes alone did not stimulate significant cellular (table 2) or humoral (data not shown) immune responses in recipient mice, even after additional boosters. Our own experience with DNA vaccination in HBV has revealed efficacy in the DNA/canarypox-based immunotherapy for chronic infection (present authors' unpublished data), and complete protection against challenge of newborn chimpanzees was induced by DNA-based immunization. Preliminary experiments in chimpanzees inoculated with mixtures of HCV pRC/capsid ϩ pRC/NS3 DNA and canarypox constructs have revealed an increase in the CTL precursor frequency responses to HCV proteins included in the DNA constructs (authors' unpublished data).
In summary, immunization with plasmid DNA and boosting with canarypox containing HCV capsid/E1/E2/NS2/NS3 genes induced cellular immune responses in mice to HCV structural and nonstructural proteins, including the envelope glycoproteins. The significance of these responses as protective immune responses against HCV infection needs to be assessed and is currently under study in chimpanzees.
